

P&T Motion History Targeted Immune Modulators (TIMs)

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
abatacept adalimumab alefacept anakinra apremilast canakinumab certolizumab pegol etanercept golimumab infliximab natalizumab rituximab secukinumab tocilizumab tofacitinib ustekinumab vedolizumab sarilumab* brodalumab* ixekizumab*	After considering the evidence of safety, efficacy, effectiveness and special populations for the use of targeted immune modulators for the treatment of immunologic conditions for which they have FDA indications, I move that: abatacept, adalimumab, alefacept, anakinra, apremilast, canakinumab, certolizumab pegol, etanercept, golimumab, infliximab, natalizumab, rituximab, secukinumab, tocilizumab, tofacitinib, ustekinumab, vedolizumab are efficacious. The PDL must include a drug approved for treatment of the following FDA indications (rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis) and should include a self-administered agent if indicated. These medications cannot be subject to therapeutic interchange in the Washington preferred drug list. Motion: Bowman 2 nd : Harvey	October 18, 2017	Yes Chew Sanderson	Yes Storhaug Brown	Passed unanimous

Bold = new this scan
 *=drugs not reviewed
10/19/2017